Evidence map›Paper›PMID 42469792›Full record

ReviewCell communication and signaling : CCS2026

Dual-recognizing antibodies targeting CEACAMs in the tumor microenvironment: towards more precise targeting.

Jiayi Ye, Yijun Zhao, Shuyang Mao, Xingxing Li, Zitong Wang, Xin Li, Xinchen Xu, Minqi Tao, Chunhai Xiao, Qingqing Huang and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cell communication and signaling : CCS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jiayi Ye *Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yijun Zhao *Graduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Shuyang MaoDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Xingxing LiGraduate School, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zitong WangDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Xin LiDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Xinchen XuDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Minqi TaoDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Chunhai XiaoJinshanBranch of Shanghai Sixth Peoples Hospital, Shanghai, China. xchwjf@163.com.
Qingqing HuangKey Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China. huangqq@sumhs.edu.cn.
Gang HuangKey Laboratory of Molecular Imaging, Shanghai University of Medicine and Health Sciences, Shanghai, China. huanggang@sumhs.edu.cn.
Wei XieDigital and Intelligent Empowerment Biomedical Innovation Center, School of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China. xiew@sumhs.edu.cn.

Funding

"AI Empowerment for Research Program" initiated by the Shanghai Municipal Education Commission (SHJWAIJK241205)Construction project of Shanghai Key Laboratory of Molecular Imaging 18DZ2260400Key supportive specialized construction project for the Health and Wellness System in Jinshan District, Shanghai (JSFCZK202102).Natural Science Foundation of Shanghai 23ZR1427400
6 · The paper itself

Abstract

The tumor microenvironment (TME) is a dynamic and constantly evolving milieu surrounding cancer cells, comprising numerous components that influence tumor growth. The Carcinoembryonic Antigen-Related Cell Adhesion Molecule (CEACAM) family has been found to be abnormally expressed in various cancers, and recent studies have highlighted its critical role in shaping and regulating the TME. Several antibody drugs targeting the CEACAM family have been developed over the last years. However, due to the physiological expression of CEACAMs in normal tissues, most of these targeted agents have yielded unsatisfactory clinical trial outcomes, characterized by significant toxicity and limited efficacy. In view of this, enhancing therapeutic efficacy while reducing adverse effects has become a focal point of current research. This review systematically summarizes the structural features of the CEACAM family and the intrinsic mechanistic differences underlying their tumor-promoting effects, and discusses the limitations of existing clinical drugs. Based on antibody optimization strategies, we propose a conceptual framework of "dual-recognition" antibodies and elaborate on precision targeting approaches at three levels-epitope, molecular, and environmental-to provide directional guidance for future investigations.

Indexed as

AntibodiesAntigens, CDCell Adhesion MoleculesNeoplasmsTumor MicroenvironmentAnimalsHumansAntibodiesAntigens, CDCD66 antigensCell Adhesion MoleculesCarcinoembryonic antigen-related cell adhesion molecule familyGlycopeptide-specific antibodyImmunotherapyTumor microenvironment

Identifiers

PMID42469792
PMCPMC13660109

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.